Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/fulltext " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Non-small cell lung cancer]]== | ==[[Non-small cell lung cancer]]== | ||
| − | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. [http://www.lungcancerjournal.info/article/S0169-5002(14)00355-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25236982 PubMed] | + | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. [http://www.lungcancerjournal.info/article/S0169-5002(14)00355-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25236982/ PubMed] |
==Also known as== | ==Also known as== | ||
Revision as of 14:40, 26 April 2023
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed
Also known as
- Code name: PGN401
- Brand name: Tarvacin